Oncogenic types of human papillomaviruses (HPVs) cause cervical cancer in humans. The antiapoptotic viral E6 gene has been identified as a key factor for maintaining the viability of HPV-positive cancer cells. Although E6 has the potential to modulate many apoptosis regulators, the crucial apoptotic pathway blocked by endogenous E6 in cervical cancer cells remained unknown. Using RNA interference (RNAi), here, we show that targeted inhibition of E6 expression in cervical cancer cells leads to the transcriptional stimulation of the PUMA promoter, in a p53-dependent manner. This is linked to the activation and translocation of Bax to the mitochondrial membrane, cytochrome c release into the cytosol, and activation of caspase-3, in a PUMA-dependent manner. Moreover, inhibition of Bax expression by RNAi efficiently reverts the apoptotic phenotype, which results from inhibition of E6 expression. Thus, interference with the p53/PUMA/ Bax cascade is crucial for the antiapoptotic function of the viral E6 oncogene in HPV-positive cancer cells.
Introduction
Certain types of human papillomaviruses (HPVs), in particular HPV16 and HPV18, are etiologically associated with the development of cervical cancer, a major cancer burden worldwide. The viral E6 and E7 oncogenes are both regularly expressed in HPV-positive tumor cells and are necessary to maintain their transformed phenotype (zur Hausen, 2002) . E6 exhibits antiapoptotic potential in various experimental settings (Pan and Griep, 1995; Sto¨ppler et al., 1998; Thomas and Banks, 1998; AguilarLemarroy et al., 2002; Filippova et al., 2004; Yuan et al., 2005) , and the targeted inhibition of endogenous E6 activity induced apoptosis in HPV-positive cancer cells (Butz et al., 2000 (Butz et al., , 2003 Hengstermann et al., 2005; Kelley et al., 2005) . Thus, the continuous presence of E6 is important for the viability of HPV-positive cancer cells, defining E6 as a promising target for therapeutic intervention.
The cellular targets that are crucial for E6-mediated inhibition of apoptosis in HPV-positive cancer cells have been poorly defined so far. Some antiapoptotic E6 activities appear to be linked to the ability of E6 to induce the proteolytic degradation of the proapoptotic p53 protein (Scheffner et al., 1990) . However, p53-independent antiapoptotic properties of E6 have been also observed (Pan and Griep, 1995; Thomas and Banks, 1998) . Moreover, ectopically expressed E6 has been associated with the modulation of a wide range of different apoptosis regulators that belong to the extrinsic, death-receptor pathway (e.g. CD95 or FADD), to the intrinsic, mitochondrial pathway (e.g. Bak or Bcl-2), or are regulators common to both pathways, such as the antiapoptotic c-IAP2 protein (Thomas and Banks, 1998; Aguilar-Lemarroy et al., 2002; Filippova et al., 2004; Yuan et al., 2005) .
It is worth noting that endogenous E6 levels are presumably very low and tightly controlled in HPV-positive cancer cells. In addition, at least some E6 activities, such as activation of telomerase, appear to be cell-type dependent (Klingelhutz et al., 1996) . These observations indicate that it is difficult to deduce the critical activities of E6 in HPV-positive cancer cells from the various effects observed after ectopic (over)expression of E6, in heterologous cell systems. In contrast to overexpression systems, the RNA interference (RNAi) technology should be useful in determining the critical functions of E6, since it allows the specific and direct inhibition of endogenous E6 expression in HPV-positive cancer cells (Butz et al., 2003) . By employing this strategy, we identified the Bax-dependent proapoptotic pathway as a critical target for the E6 oncogene and provide evidence that E6-mediated inactivation of this pathway is crucial for the protection of HPV-positive cancer cells from apoptotic cell death.
Results

Induction of PUMA following inhibition of E6 expression
The specific targeting of E6-encoding transcripts by RNAi results in an increase in p53 levels and the induction of apoptosis in HPV16 or HPV18-positive cancer cells (Butz et al., 2003; Hengstermann et al., 2005; Kelley et al., 2005) . Apoptosis, as induced by inhibition of E6 expression (in the following termed 'E6 inhibition'), appears to be p53-dependent, because HeLa cells, in which p53 expression was stably suppressed by RNAi, become resistant to siRNAs against E6 (Hengstermann et al., 2005) . Since E6 can induce the degradation of p53 (Scheffner et al., 1990) , apoptosis following siRNA-mediated E6 inhibition may be linked to the transcriptional induction of apoptosis-related p53 target genes. In a search for p53-responsive genes that are induced upon E6 inhibition, we performed filter array analyses for p53-associated genes and reproducibly observed upregulation of the proapoptotic p53 upregulated modulator of apoptosis (PUMA) gene in HPV18-positive HeLa cells (data not shown). Induction of PUMA transcripts following RNAi-mediated E6 inhibition was confirmed by RT-PCR analysis ( Figure 1a) .
To investigate whether the increase in PUMA expression was p53-dependent and whether it occurred at the transcriptional level, luciferase reporter assays were performed (Figure 1b) . The PUMA promoter contains two p53 binding sites, BS1 and BS2, the latter being the major p53-response element (Yu et al., 2001) . RNAi-mediated E6 inhibition led to an increase in PUMA promotor activities (PUMA-Frag-1). Concomitant inhibition of endogenous p53 expression by RNAi efficiently abolished activation of the PUMA promoter (Figure 1b) , indicating that p53 is the key mediator of this response. In line, PUMA induction upon E6 inhibition was linked to the presence of p53 binding sites, since a 5 0 -terminally deleted PUMA promotor, devoid of BS1 and BS2 (PUMA-Frag-2), was no longer activated ( Figure 1b) . Furthermore, four copies of BS2, upstream of a minimal promotor, were sufficient to confer transcriptional activation (BS2), whereas mutation of these sites (BS2Mut) resulted in loss of responsiveness ( Figure 1b) . In further support for the p53-dependence of the PUMA induction, we did not observe an increase in PUMA transcript levels or promoter activities upon E6 inhibition in HeLa cells in which p53 expression is suppressed by RNAi (Hengstermann et al., 2005) (data not shown). These results show that the transcriptional activities of endogenous p53 are restored upon RNAi-mediated E6 inhibition in HeLa cells and induce the PUMA promoter via its p53 recognition sites.
E6 inhibition leads to activation of Bax PUMA is a proapoptotic BH3-only protein that acts as an upstream activator of Bax, by inducing a conformational change and translocation of Bax from the cytosol to the mitochondrial membrane. This, in turn, leads to cytochrome c release from mitochondria into the cytosol, activation of caspases, and induction of apoptosis (Nakano and Vousden, 2001; Yu et al., 2001) . Thus, we analysed the Bax response in HeLa cells upon siRNA-mediated E6 inhibition. Unlike the strong upregulation of the p21 gene, bax was only modestly upregulated at both the transcript (Figure 2a ) and protein level (Figure 2b ). However, in contrast to the weak increase in total cellular Bax protein levels, E6 inhibition resulted in a strong elevation of Bax protein concentrations at mitochondria, as shown by cellular fractionation studies (Figure 2c ).
The relocalization of Bax to mitochondria was linked to increased cytochrome c levels in the cytosol and to activation of effector caspase-3 (Figure 2d ), as observed for HeLa cells overexpressing PUMA (Melino et al., 2004; S.D. unpublished) , or treated with the potent apoptosis-inducing agent staurosporine (Figure 2d ). Mitochondrial Bax translocation, cytosolic cytochrome c release, and caspase-3 activation upon E6 inhibition were PUMA-dependent, since these effects were efficiently inhibited by concomitant treatment of HeLa cells with siRNA directed against PUMA (Figure 2e and f). These results indicate that E6 inhibition in HPV-positive cancer cells ultimately leads to apoptosis via activation of Bax. To corroborate this conclusion by an independent experimental approach, we employed the anti-Bax antibody 6A7, which specifically detects the conformationally altered activated form of Bax (Hsu and Youle, 1998) . Figure 3a shows the extensive induction of apoptosis in HeLa cells upon RNAi-mediated E6 inhibition. This process was linked to strongly increased 6A7 signals that costained with a mitochondrial marker, consistent with the activation and mitochondrial translocation of Bax (Figure 3b and c).
Inhibition of Bax activation is crucial for the antiapoptotic function of E6
In view of the many different targets that have been previously implied to mediate the antiapoptotic effect of E6, we then investigated if the observed Bax activation plays a crucial role for the induction of apoptosis following E6 inhibition. In this case, concomitant silencing of endogenous Bax and E6 in HeLa cells should prevent apoptosis, which is otherwise observed upon E6 inhibition alone.
To this end, we created vector-borne siRNAs against bax mRNA, which efficiently silenced endogenous bax expression in HeLa cells, both at the RNA and protein level (Figure 4a ). Clonogenic survival assays showed that E6 inhibition by RNAi led to a strong reduction of colony numbers in HPV18-positive HeLa cells, but not in HPV-negative control cells, such as H1299 (Figure 4b ). Strikingly, concomitant inhibition of Bax expression by RNAi efficiently reverted the detrimental effect of E6 inhibition on the survival of HeLa cells, as shown for a typical example in Figure 4b and quantitated in Table 1 . RNAi-mediated bax inhibition alone did not significantly affect the colony formation capacity of HeLa cells. Taken together, these results indicate that Bax is critical for the induction of apoptotic cell death upon E6 inhibition. To exclude that the crucial connection between E6 and Bax is specific for HPV18-positive HeLa cells, we also performed clonogenic survival assays in HPV16-positive MRI-H-186 cells (Baldus et al., 2005) . Similarly as observed for HeLa cells, targeted inhibition of HPV16 E6 by RNAi also resulted in a strong inhibition of the colony formation capacity in MRI-H-186 cells, which again was counteracted by concomitant silencing of bax expression (Table 1) . HPV-negative H1299 cells were not significantly affected by siRNAs directed against HPV18 or HPV16 E6 (Table 1) .
Discussion
The results of this study show that induction of apoptosis in HPV-positive cervical cancer cells, upon targeted inhibition of E6 expression, is linked to the transcriptional stimulation of the PUMA gene via p53, and to the mitochondrial translocation and activation of Bax in a PUMA-dependent manner. Moreover, concomitant silencing of bax expression is sufficient to efficiently rescue HPV-positive cancer cells from RNAi-mediated inhibition of HPV18 E6 led to efficient induction of apoptosis in virtually all treated HeLa cells after 72 h. We did not obtain evidence for senescent cells. This is somewhat in contrast to reports indicating that E6 inhibition alone -in E7 expressing HeLa cells -not only leads to apoptosis, but also to the induction of senescence in a fraction of the cells (DeFilippis et al., 2003; Horner et al., 2004) . These differences may be due to the different experimental setups. Whereas, we specifically target endogenous E6 by RNAi (Butz et al., 2003) , the cited studies involved expression of the bovine papillomavirus (BPV) E2 protein (in order to block endogenous HPV18 E6 and E7 expression in HeLa cells) in combination with retrovirally re-expressed HPV16 E7. Both the ectopic expression of two heterologous viral proteins as well as the fact that the multifunctional BPV E2 can modulate apoptosis in HeLa cells via p53-independent mechanisms (Desaintes et al., 1999) may complicate this system.
Although bax transcription can be directly stimulated by p53 (Miyashita and Reed, 1995) , it seems unlikely that stimulation of the bax promoter is the major pathway of Bax activation upon targeted E6 inhibition in HeLa cells. We detected only a modest increase in overall bax expression, and, at most, only a marginal stimulation of the bax promoter in luciferase reporter assays (not shown), at the same experimental conditions where E6 inhibition leads to apoptosis. This lack of efficient stimulation of bax transcription may be related to the fact that the p53 binding sites within the bax promoter are relatively weak binding sites (Kong et al., 2001; Kaeser and Iggo, 2002) and hence, the levels of endogenous p53 protein restored after E6 inhibition may not suffice for efficient stimulation of bax transcription. In support of this hypothesis, a mutant bax promoter, in which the native p53 binding sites have been replaced by higher-affinity p53 recognition sites from the p21 promoter (Kong et al., 2001 ), was clearly inducible by endogenous p53 upon E6 inhibition in HeLa cells (not shown). In addition, it is possible that the recently described reduction of bax mRNA and protein levels by co-expressed E6 (Magal et al., 2005) may contribute to the slight increase of Bax expression upon inhibition of endogenous E6 expression by RNAi.
Our results rather indicate that apoptosis upon E6 inhibition is primarily due to the activation and translocation of pre-existing Bax protein to the mitochondrial membrane. These effects are mediated by PUMA, since application of siRNA against PUMA efficiently blocks the activation of Bax upon E6 inhibition. These findings, for the first time, show that targeted E6 inhibition in cervical cancer cells leads to apoptosis by the functional reconstitution of the p53/PUMA/Bax cascade and indicate that interference with this pathway is a major oncogenic activity exerted by E6. After completion of this work, a study reported Bax-dependent induction of apoptosis in HeLa cells following upon treatment with the gamma interferoninducible protein IP10 (Zhang et al., 2005) . This study differs in several aspects from our work. Whereas, we specifically target E6 by RNAi, treatment with IP10 resulted in the inhibition of both E6 and E7 expression. Yet, in contrast to studies indicating that combined E6 and E7 inhibition primarily results in senescence (Goodwin et al., 2000; Wells et al., 2000; Hall and Alexander, 2003) , induction of apoptosis was reported. In addition, IP10 is likely to exert additional biological activities besides affecting E6/E7 expression. However, possible proapoptotic effects of IP10 that are HPV-independent were not investigated. In contrast, by the RNAi approach chosen in the present work, we target the E6 gene with high specificity (Butz et al., 2003) and the apoptotic effects are selectively observed in HPV-positive cells only.
Based on our findings, we propose a model as to how the concerted action of the E6 and E7 oncogenes interfere with proper apoptosis control in HPV-positive cancer cells ( Figure 5 ). Normal cells react to abnormal growth stimuli with p53 activation and an increased apoptotic rate (Evan and Vousden, 2001 ). In HPVpositive cancer cells, E6 will block p53 and consequently interfere with transcriptional activation of the PUMA promoter and with PUMA-mediated activation of Bax, as shown in this study. In addition, E7 blocks pRb, and prevents cell cycle arrest and induction of senescence (Psyrri et al., 2004) . As a result, cervical cancer cells will resist both pRb-mediated growth arrest and p53-associated apoptosis. This model also provides a molecular explanation for the different phenotypes observed upon inhibition of E6 alone versus a combined Colony numbers of control-transfected cells set at 100%. E6 targets the PUMA/Bax Pathway M Vogt et al inhibition of E6 and E7. The combined inhibition of E6 and E7 primarily leads to growth arrest and senescence (Goodwin et al., 2000; Wells et al., 2000; Hall and Alexander, 2003) , due to the release of pRb from the inhibitory influence of E7 (Psyrri et al., 2004) . However, if growth arrest cannot be induced -due to the sustained inactivation of pRb-associated pathways by E7 -inhibition of E6 alone will result in Bax-induced apoptosis. In conclusion, we propose that survival of HPV-positive cervical cancer cells is critically dependent on E6-mediated inhibition of the p53/PUMA/Bax cascade, which otherwise is activated in response to E7-mediated inhibition of pRb.
Materials and methods
Plasmids and synthetic siRNAs siRNAs were either expressed from vector pSUPER (Brummelkamp et al., 2002) or were chemically synthesized (Dharmacon Research, Lafayette, USA). We did not observe qualitative differences between the effects of vector-borne or synthetic siRNAs. The following target sequences were used: HPV18 E6: 5 0 -CUAACACUGGGUUAUACAA-3 0 (HPV18 nucleotides (nt) 385-403) (Butz et al., 2003) 0 -UAGCGACUAAACACAU CAA-3 0 (Dharmacon Research), bears at least four mismatches to all known human genes. pSUPER-p53 as well as luciferase reporter plasmids PUMA-Frag1, PUMA-Frag 2, BS2, and BS2Mut are described in detail elsewhere (Yu et al., 2001; Brummelkamp et al., 2002) .
Cells and transfections HPV18-positive HeLa cervical carcinoma cells and HPVnegative H1299 lung cancer cells were maintained in Dulbecco's minimal essential medium (pH 7.2), supplemented with 10% fetal calf serum (FCS). HPV16-positive MRI-H-186 cervical carcinoma cells (Baldus et al., 2005) were maintained in RPMI-1640 medium supplemented with 10% FCS. Plasmids were transfected by calcium phosphate co-precipitation (Chen and Okayama, 1987) . Synthetic siRNAs were transfected with Oligofectamine (Invitrogen, Karlsruhe, Germany). In brief, cells were plated on 6 cm dishes at 30-50% confluency. For transfection, 8 ml Oligofectamine and siRNAs at a final concentration of 200 nM were both diluted in Opti-MEM I reduced serum medium (Invitrogen) and mixed in a final volume of 400 ml transfection solution. Cells were then transfected in 1.6 ml Opti-MEM I, and 4 h later supplemented with 1 ml D-MEM containing 30% FCS.
Luciferase assays
Cells were plated on 6 cm Petri dishes and transfected by calcium phosphate co-precipitation with 2 mg of the luciferase reporter plasmids and either 4 mg pSUPER, 3 mg pSUPER-18E6 plus 1 mg pSUPER, or 3 mg pSUPER-18E6 plus 1 mg pSUPER-p53, as indicated. For each transfection, 0.1 mg of the internal standard CMV-Gal was included. At 60 h after transfection, cells were harvested, and luciferase activities were determined as detailed elsewhere (Butz et al., 2003) .
RNA and protein preparations, cellular fractionation RNA and whole cell protein extracts were prepared as previously described (Butz et al., 2003) . For cytochrome c detection, cytosolic protein extracts were generated as described by Samali et al. (1999) . For the detection of Bax translocation, mitochondria-enriched and cytosolic extracts were prepared following the protocol of Liu et al. (2004) . In brief, cells were trypsinized, washed twice with icecold PBS and resuspended in 500-600 ml homogenization buffer (250 mM sucrose, 10 mM HEPES, 1 mM EGTA, pH 7.4) supplemented with 25 ml/ml buffer Pefabloc (20 mg/ml, Merck, Darmstadt, Germany) and 10 ml/ml buffer protease Inhibitor Cocktail (Sigma-Aldrich, Munich, Germany). After incubation for 30 min on ice, the resuspended cells were homogenized in a 2 ml tissue grinder (Kontes, Vineland, USA) on ice, with 20-40 strokes using a B type pestle. The homogenates were centrifuged at 2300 g for 5 min and subsequently at 900 g for 10 min at 41C. Supernatants were centrifuged at 20 000 g for 15 min at 41C and the resulting mitochondrial pellets were resuspended in homogenization buffer. The supernatants of the 20 000 g spin were again centrifuged at 20 000 g for 15 min at 41C and the resulting supernatants (cytosolic extracts) were stored at À701C.
Protein and RNA analyses
For Western Blot analyses, cellular extracts were separated by 12.5%. SDS-PAGE, transferred to an Immobilon-P membrane (Millipore, Eschborn, Germany) and analysed by enhanced chemiluminescence (Amersham Biosciences, Freiburg, Germany). The following antibodies were used for detection: anti-p21 WAFÀ1 OP64 (Calbiochem, Schwalbach, Germany), anti-Bax N-20 (Santa Cruz Biotechnology, Santa Cruz, USA), anti-VDAC PA1-954 (Dianova, Hamburg, Germany), anti-cytochrome c H-104 (Santa Cruz Biotechnology), anti-active caspase 3 CM-1 (BD Pharmingen, San Diego, USA), and anti-a-tubulin CP06 (Calbiochem). Immunofluorescence studies for the detection of activated Bax were performed using anti-Bax antibody 6A7 (BD Pharmingen), mitochondria were stained with MitoTracker Deep Red (Invitrogen). Northern blots were performed as described before (Butz et al., 2003) . For normalisation, membranes were reprobed with Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). RT-PCR analyses for PUMA expression were performed using primers PUMA-for: 5 0 -TCCTC AGCCCTCGCTCTC-3 0 (nt 557-574) and PUMA-rev: 5 0 -TCCCATGATGAGATTGTACAGG-3 0 (nt 812-791) employing the Platinum Pfx DNA polymerase (Invitrogen) for GC-rich templates. GAPDH transcripts were amplified with Taq DNA polymerase (Invitrogen), using primers GAPDHfor: 5 0 -GAAGGTGAAGGTCGGAGTC-3 0 (nt 1458-1476) and GAPDH-rev: 5 0 -GAAGATGGTGATGGGATTTC-3 0 (nt 3407-3388). Amplification products were stained with ethidium bromide.
Colony formation assays, detection of apoptosis Cells were grown on 6 cm dishes and transfected with pSUPER vectors, as indicated, together with 0.2 mg pSV2Neo to allow for the selection of transfected cells by neomycin resistance (Butz et al., 2003) . HeLa cells were transfected with either 6 mg pSUPER (control), 2 mg pSUPER-18E6 plus 4 mg pSUPER, 2 mg pSUPER-18E6 plus 4 mg pSUPER-Bax, or 2 mg pSUPER-plus 4 mg pSUPER-Bax. MRI-H-186 cells were transfected with either 6 mg pSUPER (control), 3 mg pSUPER-16E6 plus 3 mg pSUPER, 3 mg pSUPER-16E6 plus 3 mg pSUPER-Bax, or 3 mg pSUPER plus 3 mg pSUPER-Bax. After 6-7 days selection for G418 (Invitrogen) resistance, colonies E6 targets the PUMA/Bax Pathway M Vogt et al were fixed with formaldehyde and stained with crystal violet. For detection of apoptosis, TdT-mediated dUTP nick end labeling (TUNEL) analyses were performed, using the in situ cell death detection kit (Roche Molecular Biochemicals). Nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Roche Molecular Biochemicals). Apoptotic strand breaks and total DNA were visualized by epifluorescence microscopy.
